Isovaleric Acidemia is treated with L-leucine restriction and supplemental glycine. Added glycine augments conversion of isovaleric acid (IVA) to isovalerylglycine (IVG) through glycine-N-acylase.

The global isovaleric acidemia treatment market is poised for remarkable growth, projected to rise from USD 652.28 million in 2023 to USD 1,125.15 million by 2033, reflecting a robust CAGR of 5.6%.